Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia

Experimental Hematology

Volumn 41, Issue 7, 2013, Pages 615-626

  Palma, Marzia ^a,b   Parker, Anton ^c   Hojjat Farsangi, Mohammad ^a   Forster, Jade ^c   Kokhaei, Parviz ^a,d   Hansson, Lotta ^a,b   Österborg, Anders ^a,b   Mellstedt, Håkan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CD34 SELECTION; CHROMOSOMAL PARAMETERS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN VARIABLE GENE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLICING DEFECT; TELOMERE LENGTH;

AGED; ALTERNATIVE SPLICING; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; ISOENZYMES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TELOMERASE; TELOMERE;

EID: 84879602744     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.03.008     Document Type: Article

References (49)

1. Gribben J.G. How I treat CLL up front. Blood 2010, 115:187-197.
2. Van Bockstaele F., Verhasselt B., Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009, 23:25-47.
3. Blackburn E.H., Greider C.W., Henderson E., Lee M.S., Shampay J., Shippen-Lentz D. Recognition and elongation of telomeres by telomerase. Genome 1989, 31:553-560.
4. Nilsson P., Mehle C., Remes K., Roos G. Telomerase activity invivo in human malignant hematopoietic cells. Oncogene 1994, 9:3043-3048.
5. Broccoli D., Young J.W., de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A 1995, 92:9082-9086.
6. Nabetani A., Ishikawa F. Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells. J Biochem 2011, 149:5-14.
7. Chang M.W., Grillari J., Mayrhofer C., et al. Comparison of early passage, senescent and hTERT immortalized endothelial cells. Exp Cell Res 2005, 309:121-136.
8. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
9. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791.
10. Meeker A.K., Coffey D.S. Telomerase: a promising marker of biological immortality of germ, stem, and cancer cells. A review. Biochemistry (Mosc) 1997, 62:1323-1331.
11. Trentin L., Ballon G., Ometto L., et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 1999, 106:662-668.
12. Damle R.N., Batliwalla F.M., Ghiotto F., et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004, 103:375-382.
13. Rossi D., Lobetti Bodoni C., Genuardi E., et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009, 23:1062-1072.
14. Roos G., Krober A., Grabowski P., et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008, 111:2246-2252.
15. Brugat T, Gault N, Baccelli I, etal. Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. Leukemia;24:246-251.
16. Poncet D., Belleville A., t'kint de Roodenbeke C., et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 2008, 111:2388-2391.
17. Batliwalla F.M., Damle R.N., Metz C., Chiorazzi N., Gregersen P.K. Simultaneous flow cytometric analysis of cell surface markers and telomere length: analysis of human tonsilar B cells. J Immunol Methods 2001, 247:103-109.
18. Hu B.T., Lee S.C., Marin E., Ryan D.H., Insel R.A. Telomerase is up-regulated in human germinal center B cells invivo and can be re-expressed in memory B cells activated invitro. J Immunol 1997, 159:1068-1071.
19. Norrback K.F., Hultdin M., Dahlenborg K., Osterman P., Carlsson R., Roos G. Telomerase regulation and telomere dynamics in germinal centers. Eur J Haematol 2001, 67:309-317.
20. Weng N.P., Granger L., Hodes R.J. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci U S A 1997, 94:10827-10832.
21. Damle R.N., Temburni S., Banapour T., et al. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients. Blood 2012, 120:2438-2449.
22. Meyerson M., Counter C.M., Eaton E.N., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
23. Kirkpatrick K.L., Mokbel K. The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur J Surg Oncol 2001, 27:754-760.
24. Ohyashiki J.H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002, 21:680-687.
25. Terrin L., Trentin L., Degan M., et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 2007, 21:965-972.
26. Saeboe-Larssen S., Fossberg E., Gaudernack G. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): Analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Mol Biol 2006, 7:26.
27. Ulaner G.A., Hu J.F., Vu T.H., Giudice L.C., Hoffman A.R. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998, 58:4168-4172.
28. Ulaner G.A., Hu J.F., Vu T.H., Giudice L.C., Hoffman A.R. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer 2001, 91:644-649.
29. Ulaner G.A., Hu J.F., Vu T.H., Oruganti H., Giudice L.C., Hoffman A.R. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 2000, 85:330-335.
30. Colgin L.M., Wilkinson C., Englezou A., Kilian A., Robinson M.O., Reddel R.R. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000, 2:426-432.
31. Yi X., White D.M., Aisner D.L., Baur J.A., Wright W.E., Shay J.W. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2000, 2:433-440.
32. Tchirkov A., Chaleteix C., Magnac C., et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol 2004, 15:1476-1480.
33. Aisner D.L., Wright W.E., Shay J.W. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002, 12:80-85.
34. Fan Y., Liu Z., Fang X., et al. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res 2005, 11:4331-4337.
35. Kyo S., Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy?. Oncogene 2002, 21:688-697.
36. Flores I., Benetti R., Blasco M.A. Telomerase regulation and stem cell behaviour. Curr Opin Cell Biol 2006, 18:254-260.
37. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
38. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
39. Kokhaei P., Palma M., Hansson L., Osterborg A., Mellstedt H., Choudhury A. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007, 35:297-304.
40. Cawthon R.M. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 2009, 37:e21.
41. Grabowski P., Hultdin M., Karlsson K., et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005, 105:4807-4812.
42. Hultdin M., Rosenquist R., Thunberg U., et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2003, 88:593-598.
43. Yi X., Shay J.W., Wright W.E. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 2001, 29:4818-4825.
44. Zaffaroni N., Della Porta C., Villa R., et al. Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. J Pathol 2002, 198:37-46.
45. Mavrogiannou E., Strati A., Stathopoulou A., Tsaroucha E.G., Kaklamanis L., Lianidou E.S. Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer. Clin Chem 2007, 53:53-61.
46. Lincz L.F., Mudge L.M., Scorgie F.E., Sakoff J.A., Hamilton C.S., Seldon M. Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variant. Neoplasia 2008, 10:1131-1137.
47. Wang Y., Kowalski J., Tsai H.L., et al. Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid 2008, 18:1055-1063.
48. Brinkman B.M. Splice variants as cancer biomarkers. Clin Biochem 2004, 37:584-594.
49. Kalnina Z., Zayakin P., Silina K., Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005, 42:342-357.